CorMedix Inc. (CRMD) Dividend History

CorMedix Inc. is a healthcare company focused on developing and commercializing medical therapies for the prevention and containment of infections in hospital settings, particularly through its flagship product, Neutrolin, a patented antimicrobial solution used in central venous catheters to reduce bloodstream infections.

300 Connell Drive, Berkeley Heights, NJ, 07922
Phone: 908-517-9500
Website:

Dividend History

CorMedix Inc. currently does not pay dividends

Company News

  • Closed System Transfer Device Market Size Poised to Hit USD 4,753.71 million by 2034, Driven by a 14.1% CAGR | PMR

    The global closed system transfer device market is projected to grow from $1.1 billion in 2024 to $4.8 billion by 2034, driven by advancements in technology and increasing cancer cases worldwide.

    GlobeNewswire Inc.
    Featured Companies: BAX ICUI
  • Here's Why CorMedix Is a Great 'Buy the Bottom' Stock Now

    CorMedix (CRMD) stock has been struggling, but a hammer chart pattern and strong earnings estimate revisions suggest a potential trend reversal. The article highlights the technical and fundamental factors that make CRMD a good 'buy the bottom' stock.

    Benzinga
  • CorMedix Inc. Announces New Commercial Agreement

    CorMedix Inc. has entered into a multi-year commercial supply contract with a global healthcare company for the supply of its approved product DefenCath, which is used to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis.

    GlobeNewswire Inc.
  • CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath

    BERKELEY HEIGHTS, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System (OPPS). Pass-through status provides for separate payment under Medicare Part B for the utilization of DefenCath in the out-patient ambulatory setting for a period of at least two years, and up to a maximum of three years.

    GlobeNewswire Inc.
  • CorMedix (CRMD) Q1 2024 Earnings Call Transcript

    CRMD earnings call for the period ending March 31, 2024.

    The Motley Fool
Dividend data last updated 06/07/2025 02:03:11 UTC